July 2015, Special ASCO Edition

← Back to Issue

Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma


Combination treatment with the immunotherapies nivolumab and ipilimumab led to a doubling in progression-free survival (PFS) compared with ipilimumab alone in patients with advanced melanoma, investigators from the CheckMate 067 trial reported.

The study also suggested promise for programmed death-1 (PD-1) ligand 1 (PD-L1) as a biomarker of response that could help determine whether patients would benefit most from 1 or from 2 forms of immunotherapy, said Jedd D. Wolchok, MD, PhD, Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center, New York City.

“Based upon the available evidence, the combination represents a means to improve outcomes, versus nivolumab alone, particularly for patients whose tumors have <5% PD-L1 expression,” Wolchok said.

Patients who expressed PD-L1 derived essentially as much benefit from single-agent nivolumab as from the combination of nivolumab and ipilimumab, he said.

The important findings were presented at a plenary session at ASCO 2015. Results of the phase 2 clinical trial were presented earlier this year.

The CheckMate 067 Phase 3 Trial

CheckMate 067 was the first phase 3 clinical trial to evaluate the combination of a PD-1 inhibitor and a cytotoxic T-lymphocyte antigen-4 inhibitor. The trial randomized 945 treatment-naive patients with advanced or metastatic melanoma in a 1:1:1 fashion to 1 of 3 arms: 1) nivolumab 1 mg/kg every 2 weeks plus ipilimumab 3 mg/kg every 3 week for 4 doses, followed by nivolumab 3 mg/kg every 2 weeks; 2) nivolumab 3 mg/kg every 2 weeks plus placebo; or 3) ipilimumab 3 mg/kg every 3 weeks for 4 doses plus placebo, until disease progression or unacceptable toxicity.

The study’s coprimary end points were PFS with nivolumab alone and PFS with nivolumab plus ipilimumab versus ipilimumab alone.

“Nivolumab alone and nivolumab plus ipilimumab significantly improved progression-free survival and objective response rates versus ipilimumab alone in patients with previously untreated melanoma,” Wolchok said.

In the overall population, the median PFS was 11.5 months with the combination (hazard ratio [HR], 0.42 vs ipilimu­mab; P <.001), 6.9 months with nivolumab alone (HR, 0.57 vs ipilimumab; P <.001), and 2.9 months with ipilimumab alone.

The combination also produced a higher response rate of 57.6% versus 43.7% with nivolumab alone and 19.0% for ipilimumab alone; both nivolumab-containing arms were statistically significant versus the ipilimumab monotherapy arm (P <.001).

The duration of response in all 3 arms was not yet reached at a minimum follow-up of 9 months. The median change in tumor burden was –51.9% with the combination, –34.5% with nivolumab alone, and +5.9% with ipilimumab alone.

The Importance of PD-L1 Expression

PD-L1 expression defined a group of patients with melanoma whose outcomes were different from the overall study population. In patients whose tumors had at least a 5% PD-L1 expression, nivolumab alone and nivolumab plus ipilimumab resulted in a similar prolongation in PFS, 14 months in each arm, versus 3.9 months with ipilimumab alone, Wolchok reported.

Steven O’Day, MD, a melanoma expert, commented, “Right now, in PD-L1–positive patients, we can be fairly reassured that their progression-free survival will be very similar,” whether they receive a single-agent anti–PD-1 agent or 2 immunotherapies together.

The dual immunotherapy regimen proved to be relatively well tolerated, although 55% of patients had grade 3/4 adverse events compared with 16.3% of patients receiving nivolumab and 27.3% receiving ipilimumab, Wolchok reported. These side effects were consistent with previous reports.

“We had no drug-related deaths in the combination arm. This is a very important point, because the trial was conducted in 137 sites globally. Safety guidelines were put into place so that physicians in a variety of venues were able to handle the side effects,” he said.

Superior Combination

Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Cancer Center, Washington, DC, discussed CheckMate 067 at the plenary session, commenting, “Nivolumab and nivolu­mab plus ipilimumab are superior to ipi­limumab. These treatments (along with pembrolizumab) are a new standard for advanced melanoma therapy.”

However, Atkins objected to the concept of PD-L1 as a biomarker, at least at this point. “PD-L1 must be viewed as a weak biomarker,” he maintained.

For a number of reasons, he said, PD-L1 and its assays need to be validated before PD-L1 can be used for clinical decision making.

Atkins added that based on available data on the 2 PD-1 inhibitors, nivolu­mab and pembrolizumab have no “clear-cut distinction of therapeutic index.”

In the absence of a clinical trial, he believes physicians will choose them based on factors such as dosing schedule, clinical experience, marketing, predictability of biomarkers, and cost.

Breast Cancer - August 13, 2015

T-DM1 Not Superior to Standard of Care in First-Line Metastatic Breast Cancer

The standard of care for previously untreated HER2-positive metastatic breast cancer remains taxane/trastuzumab/pertuzumab, according to results from the MARIANNE trial, which evaluated trastuzumab emtansine (T-DM1) in this setting. While T-DM1 was not inferior to trastuzumab/taxane (HT), it did not improve outcomes over the control arm and, therefore, does not merit [ Read More ]

Value-Based Cancer Care - August 13, 2015

Cost-Effectiveness of T-DM1 Examined

For the treatment of advanced HER2-positive breast cancer, the use of trastuzumab emtansine (T-DM1) is not cost-effective when compared with lapatinib plus capecitabine from both a societal and a payer’s perspective, according to an analysis conducted at Western University of Health Sciences College of Pharmacy in Pomona, CA. From a [ Read More ]